John Mulvihill

Dr. John Mulvihill


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2020 in Nanomedicine
Verified
Journal Article
Closed access
JMJohn Mulvihill
John Mulvihill
ECEoghan M Cunnane
Eoghan M Cunnane
ARAisling Ross
Aisling Ross
Jason DuskeyJason Duskey
Jason Duskey
Giovanni TosiGiovanni Tosi
Giovanni Tosi
Andreas GrabruckerAndreas Grabrucker
Andreas Grabrucker
The blood–brain barrier (BBB) has a significant contribution to homeostasis and protection of the CNS. However, it also limits the crossing of therapeutics and thereby complicates the treatment of ...

1 March 2014 in Journal of Biomechanics
Verified
Journal Article
Closed access
Gerhard A. HolzapfelGerhard A. Holzapfel
Gerhard A. Holzapfel
JMJohn Mulvihill
John Mulvihill
ECEoghan Cunnane
Eoghan Cunnane
MWMichael T Walsh
Michael T Walsh

1 March 2014 in Journal of Biomechanics
Verified
Journal Article
Closed access
MWMichael T Walsh
Michael T Walsh
ECEoghan Cunnane
Eoghan Cunnane
JMJohn Mulvihill
John Mulvihill
AAAli Cagdas Akyildiz
Ali Cagdas Akyildiz
FGF.J.H. Gijsen
F.J.H. Gijsen
GHG.A. Holzapfel
G.A. Holzapfel

1 September 2018 in Journal of Trace Elements in Medicine and Biology
Verified
Journal Article
Open access
AVAntonietta Vilella
Antonietta Vilella
DBDaniela Belletti
Daniela Belletti
ASAnn Katrin Sauer
Ann Katrin Sauer
SHSimone Hagmeyer
Simone Hagmeyer
TSTasnuva Sarowar
Tasnuva Sarowar
Andreas GrabruckerAndreas Grabrucker
Andreas Grabrucker
A local dyshomeostasis of zinc ions in the vicinity of amyloid aggregates has been proposed in Alzheimer's disease (AD) due to the sequestration of zinc in senile plaques. While an increase in zinc levels may promote the aggregation of amyloid beta (Aβ), increased brain zinc might also be beneficial rescuing some pathological alterations caused by local zinc deficiency. For example, increased Aβ degradation by metalloproteinases, and a reduction in inflammation can be hypothesized. In addition, zinc may allow a stabilization of the number of synapses in AD brains. Thus, to evaluate whether altering zinc-levels within the brain is a promising new target for the prevention and treatment of AD, we employed novel zinc loaded nanoparticles able to deliver zinc into the brain across the blood-brain barrier. We performed in vivo studies using wild type (WT) and APP23 mice to assess plaque load, inflammatory status and synapse loss. Furthermore, we performed behavioral analyses. After chronically injecting these nanoparticles for 14 days, our results show a significant reduction in plaque size and effects on the pro-inflammatory cytokines IL-6 and IL-18. On behavioral level we could not detect negative effects of increased brain zinc levels in APP23 mice and treatment with g7-NP-Zn normalized the observed hyperlocomotion of APP23 mice. Therefore, we conclude that a targeted increase in brain zinc levels may have beneficial effects in AD.

1 May 2016 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
BCBaptiste Coudrillier
Baptiste Coudrillier
ICIan C. Campbell
Ian C. Campbell
ARA. Thomas Read
A. Thomas Read
DGDiogo M. Geraldes
Diogo M. Geraldes
NVNghia T. Vo
Nghia T. Vo
CEC. Ross Ethier
C. Ross Ethier
Purpose: Scleral stiffening has been proposed as a treatment for glaucoma to protect the lamina cribrosa (LC) from excessive intraocular pressure–induced deformation. Here we experimentally evaluated the effects of moderate stiffening of the peripapillary sclera on the deformation of the LC. Methods: An annular sponge, saturated with 1.25% glutaraldehyde, was applied to the external surface of the peripapillary sclera for 5 minutes to stiffen the sclera. Tissue deformation was quantified in two groups of porcine eyes, using digital image correlation (DIC) or computed tomography imaging and digital volume correlation (DVC). In group A (n = 14), eyes were subjected to inflation testing before and after scleral stiffening. Digital image correlation was used to measure scleral deformation and quantify the magnitude of scleral stiffening. In group B (n = 5), the optic nerve head region was imaged using synchrotron radiation phase-contrast microcomputed tomography (PC μCT) at an isotropic spatial resolution of 3.2 μm. Digital volume correlation was used to compute the full-field three-dimensional deformation within the LC and evaluate the effects of peripapillary scleral cross-linking on LC biomechanics. Results: On average, scleral treatment with glutaraldehyde caused a 34 ± 14% stiffening of the peripapillary sclera measured at 17 mm Hg and a 47 ± 12% decrease in the maximum tensile strain in the LC measured at 15 mm Hg. The reduction in LC strains was not due to cross-linking of the LC. Conclusions: Peripapillary scleral stiffening is effective at reducing the magnitude of biomechanical strains within the LC. Its potential and future utilization in glaucoma axonal neuroprotection requires further investigation.

1 February 2015 in Journal of the Mechanical Behavior of Biomedical Materials
Verified
Journal Article
Closed access
SOSiobhan A. O’lEary
Siobhan A. O’lEary
JMJohn Mulvihill
John Mulvihill
HBHilary E. Barrett
Hilary E. Barrett
EKEamon G. Kavanagh
Eamon G. Kavanagh
MWMichael T Walsh
Michael T Walsh
BDBarry J. Doyle
Barry J. Doyle